#EliLilly's bid to dominate the next generation of #weightlosstherapies has been strengthened by data on a new #combinationtherapy that combines its GIP/GLP-1 agonist tirzepatide with amylin-targeting eloralintide.
@pharmaphorum.bsky.socialExplore
@pharmaphorum.bsky.social@pharmaphorum.bsky.socialThere has been a flurry of #clinicalreadouts for new #weightlosstherapies in the last few days, with #Roche, #VikingTherapeutics, and #Syntis all showing off new drug candidates.
